Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Jul 10, 2026
Reporting period
Not applicable
Filed with the SEC
Jul 14, 2026
CEOTax withholding
Context
Classification
tax withholding
Code F — shares delivered to pay exercise price or tax liability
Planned / mechanical clue
Tax mechanics (code F)
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001104659-26-083516
Filed / recorded
Jul 14, 2026, 8:18 PM UTC
Added to OQRO
Oct 8, 2026, 1:45 AM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
Armata Pharmaceuticals, Inc.
Issuer CIK
921114
Ticker
ARMP
Reporting person
Deborah Birx
Relationship
Director, Officer
Officer title
Chief Executive Officer
Security
Common Stock
Table
Non-derivative (Table I)
Transaction date
Jul 10, 2026
Transaction code
F
Shares / units
14,041
Price per share
$4.26
Acquired / disposed
Disposed (D)
Shares owned after
198,417
Ownership form
Direct
Amendment
No
Footnotes from the filing
Represents shares that have been withheld by the Company to satisfy its income tax and withholding remittance obligations in connection with the net settlement of restricted stock units.
Among this manager's largest new positions for Q1 2026. From a 13F filed May 7, 2026 covering holdings at Mar 31, 2026 — a quarter-end snapshot, not a live trade.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.